Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONE: Individualized vs Conventional Transfusion Strategy in VA-ECMO for Cardiogenic Shock
NCT05699005Phase 1Recruiting
- Sponsor
- CHU de Lille
- Start
- Sep 2023
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of red blood cells in anemia (2 arms), sponsored by CHU de Lille. Primary endpoint: Number of PRBCs transfused per VA-ECMO day of support at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
red blood cells
03
Conditions
anemia
Beyond the preview
Go deeper on NCT05699005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699005.